Skip to main content
Login
institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published • loading... • Updated

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Summary by Denton Record-Chronicle
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).

17 Articles

Denton Record-ChronicleDenton Record-Chronicle
+15 Reposted by 15 other sources
Center

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin

Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder (MDD).

·Denton, United States
Read Full Article
lifesciencesbc.califesciencesbc.ca

AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin - Life Sciences British Columbia

NORTH CHICAGO, Ill - AbbVie  announced its completed its acquisition of Gilgamesh Pharmaceuticals, bretisilocin.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center

Factuality 

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Friday, October 17, 2025.
Sources are mostly out of (0)

Similar News Topics

United States icon

United States

News
For You
SearchBlindspotLocal